Aytu BioPharma, Inc. (LON: 0A8M)

Market Cap	8.59M
Revenue (ttm)	59.51M
Net Income (ttm)	-4.66M
Shares Out	n/a
EPS (ttm)	-1.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63
Average Volume	309
Open	1.778
Previous Close	1.815
Day's Range	1.750 - 1.789
52-Week Range	1.083 - 2.761
Beta	n/a
RSI	50.64
Earnings Date	Feb 13, 2025

About Aytu BioPharma

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to trea...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Joshua Disbrow
• Employees: 102
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A8M

Financial Performance

In 2024, Aytu BioPharma's revenue was $81.00 million, a decrease of -24.58% compared to the previous year's $107.40 million. Losses were -$15.84 million, -7.08% less than in 2023.

Financial numbers in USD